Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2007, Article ID 12367, 3 pages
http://dx.doi.org/10.1155/2007/12367
Clinical Study

Insights to Clinical Use of Serial Determination in Titers of Cyclic Citrullinated Peptide Autoantibodies

1Department of Integrated Japanese Oriental Medicine, School of Medicine, Gunma University, Maebashi, Gunma 371-8511, Japan
2Division of Japanese Oriental Medicine, Department of Internal Medicine, Toyama Prefectural Central Hospital, 2-2-78 Nishinagae, Toyama 930-8550, Japan
3Department of Japanese Oriental Medicine, Kanebo Memorial hospital, Kobe, Hyogo 652-0855, Japan
4Department of Japanese Oriental Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan

Received 14 December 2006; Revised 25 January 2007; Accepted 25 January 2007

Copyright © 2007 Toshiaki Kogure et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Shovman, B. Gilburd, G. Zandman-Goddard et al., “The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis,” Clinical and Developmental Immunology, vol. 12, no. 3, pp. 197–202, 2005. View at Publisher · View at Google Scholar
  2. K. Raza, M. Breese, P. Nightingale et al., “Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis,” Journal of Rheumatology, vol. 32, no. 2, pp. 231–238, 2005. View at Google Scholar
  3. E. Lindqvist, K. Eberhardt, K. Bendtzen, D. Heinegȧrd, and T. Saxne, “Prognostic laboratory markers of joint damage in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. 196–201, 2005. View at Publisher · View at Google Scholar
  4. O. Meyer, P. Nicaise-Roland, M. dos Santos et al., “Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis,” Arthritis Research & Therapy, vol. 8, no. 2, p. R40, 2006. View at Publisher · View at Google Scholar
  5. A. Larsen, K. Dale, and M. Eek, “Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films,” Acta Radiologica Diagnosis, vol. 18, no. 4, pp. 481–491, 1977. View at Google Scholar
  6. E. Lindqvist, K. Jonsson, T. Saxne, and K. Eberhardt, “Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 62, no. 7, pp. 611–616, 2003. View at Publisher · View at Google Scholar
  7. L. De Rycke, X. Verhelst, E. Kruithof et al., “Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. 299–302, 2005. View at Publisher · View at Google Scholar
  8. P. Caramaschi, D. Biasi, E. Tonolli et al., “Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment,” Rheumatology International, vol. 26, no. 1, pp. 58–62, 2005. View at Publisher · View at Google Scholar